Alginate based nanoparticulate drug delivery for anti HIV drug lopinavir

Journal of Global Pharma Technology

Volumn 2, Issue 3, 2010, Pages 126-132

  Angshuman, B ^a   Bhattacharjee, S K ^a   Rita, Mahanta ^b   Maity, Biswanath ^c   Bandyopadhayay, S K ^c  

^a GAUHATI UNIVERSITY   (India)

^b Wildlife Biology and Conservation Group Department of Environmental Biology and Wildlife Sciences   (India)

^c INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Alginate; Dichloromethane; Lopinavir

Indexed keywords

1,2 DICHLOROETHANE; 2 PROPANOL; CALCIUM ALGINATE; DICHLOROMETHANE; HEXANE; LOPINAVIR; NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; CROSS LINKING; DIFFUSION; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HYDRODYNAMICS; IN VITRO STUDY; MEAN RESIDENCE TIME; MOUSE; NANOEMULSION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; QUANTITATIVE ANALYSIS; SURFACE PROPERTY; SUSTAINED DRUG RELEASE;

EID: 79952661797     PISSN: None     EISSN: 09758542     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kataoka K., Matsumoto T., Yokoyama M., Okano S. Fukushima Y., Okamoto K., Kwon G.S. Doxorubicin-loaded poly (ethylene glycol)-poly (β-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control Release 2000; 64:143-53.
2. Couvreur P., Barratt G., Fattal E., Legrand P., Vauthier C. Nanocapsule technology: A review. Crit Rev Ther. Drug Carrier Syst. 2002; 19: 99.
3. Alyautdin R., Gothier D., Petrov D., Kharkevich., Kreuter J. Analgesic activity of the hexapeptide dalagin adsorbed on the surgace of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 1995; 41:44-48.
4. Markowitz, M. H. HIV Patogenisis and Viral Dynamics. Antiviral Therapy1997; 2: 7-17.
5. Fauci, A. S. The Human Immunodeficiency Virus - Infectivity and Mechanisms of Pathogenesis. Science. 1988; 239: 617-22.
6. Ho D. D., Pomerantz R., Kaplan J. J. C. Pathogenesis of Infection with Human-Immunodeficiency-Virus. N Eng. J. Med. 1987; 317: 278-86.
7. Chu C.M. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax.2004; 59: 252-56.
8. Hurst M., Faulds D. Lopinavir. Drugs. 2000; 60: 1371-79.
9. Cvetkovic R.S., Goa K.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003; 63: 769-802.
10. Indian Pharmacopoeia. India Pharmacopoeial Commission. 2007; 2: 1315.
11. Ekman B., Sjoholm I. Incorporation of macromolecules in microparticles: preparation and characteristics. Biochem. 1976; 15: 115.
12. Polakovic., Gorner M., Gref T., Dellacherie. Lidocaine loaded biodegradable nanospheres II. Modelling of drug release. J. Control Rel. 1999; 60:169-177.
13. Pitt., Gratzi C.G., Jeffcoat M.M., Zweidinger A.R., Schinler A. Sustained drug delivery systems. II. Factors affecting release rates from poly (ε -caprolactone) and related biodegradable polyesters. J. Pharm Sci.1979; 68: 1534-38.
14. Peppas N. A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta. Helv. 1985; 60:110-11.
15. Ritger P. L., Peppas N.A. A simple equation for description of solute release Fickian and anomalous release from swellable devices. J. Control Rel. 1987; 5: 37-42.
16. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Advances in Drug Delivery Reviews 2001; 47: 65-81.
17. Kreuter J., Shamenko V., Petrov D., Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Targeting.2002; 10: 317-25.